drugset / Trial / NCT04954040
Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
Multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.
Timeline
- Start
- 2021-02-10
- Primary completion
- 2021-10
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |